三阳性乳腺癌新辅助治疗研究现状
Research Progress on Neoadjuvant Systemic Therapy for Triple-Positive Breast Cancer
DOI: 10.12677/acm.2026.1651910, PDF,   
作者: 缪林芮, 涂 刚*：重庆医科大学附属第一医院乳腺甲状腺外科，重庆
关键词: 三阳性乳腺癌；新辅助治疗；精准医学；Triple-Positive Breast Cancer； Neoadjuvant Systemic Therapy； Precision Medicine
摘要: 三阳性乳腺癌(TPBC)是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)均呈阳性表达的乳腺癌亚型，具有独特的肿瘤行为和治疗反应。本文系统叙述了TPBC新辅助治疗的研究进展，尽管以蒽环类联合紫杉烷类为基础的化疗仍是标准骨架，但其疗效受限于耐药性和毒副作用。抗HER2靶向治疗能够显著提高HER2阳性乳腺癌患者的病理完全缓解率(pCR)，新型抗体偶联药物(ADCs)在克服耐药和改善预后方面更是展现出突破性潜力。细胞周期依赖性激酶4/6 (CDK4/6)抑制剂为克服内分泌治疗耐药提供了新思路，新型口服内分泌治疗药物如完全雌激素受体拮抗剂(CERAN)等的开发也为激素受体(HR)阳性表达的乳腺癌患者带来了新的治疗可能。当前，多维度生物标志物分层治疗策略和液体活检等动态监测技术正推动TPBC新辅助治疗迈向精准化时代，真实世界数据库的建立与完善将进一步提升治疗的实用性与安全性。
Abstract: Triple-positive breast cancer (TPBC), defined by the co-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), exhibits distinct tumor biology and therapeutic behavior. This review systematically summarizes the recent advances in neoadjuvant systemic therapy (NST) for TPBC. Although anthracyclines combined with taxanes remain the standard chemotherapy regimen, their efficacy is frequently limited by drug resistance and toxicity. Anti-HER2 targeted therapy can significantly improve pathological complete response (pCR) rates in HER2-positive breast cancer. Novel antibody-drug conjugates (ADCs) have demonstrated breakthrough potential in overcoming resistance and improving prognosis. Given the intracellular crosstalk between ER and HER2 signaling pathways, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors offer a promising strategy to overcome endocrine therapy resistance. In parallel, the development of novel endocrine agents provides new therapeutic opportunities for patients with hormone receptor (HR)-positive disease. Currently, the integration of multi-dimensional biomarker-driven strategies and dynamic monitoring technologies are propelling neoadjuvant systemic therapy into an era of precision medicine. The establishment and refinement of real-world databases for TPBC patients will further enhance the applicability and safety of these therapeutic approaches.
文章引用：缪林芮, 涂刚. 三阳性乳腺癌新辅助治疗研究现状[J]. 临床医学进展, 2026, 16(5): 1114-1124. https://doi.org/10.12677/acm.2026.1651910

参考文献

[1] Swarbrick, A., Fernandez-Martinez, A. and Perou, C.M. (2024) Gene-Expression Profiling to Decipher Breast Cancer Inter-and Intratumor Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 14, a041320. [Google Scholar] [CrossRef] [PubMed]
[2] Boscolo Bielo, L., Trapani, D., Nicolò, E., Valenza, C., Guidi, L., Belli, C., et al. (2024) The Evolving Landscape of Metastatic HER2-Positive, Hormone Receptor-Positive Breast Cancer. Cancer Treatment Reviews, 128, Article ID: 102761. [Google Scholar] [CrossRef] [PubMed]
[3] Debien, V., de Azambuja, E. and Piccart-Gebhart, M. (2023) Optimizing Treatment for HER2-Positive HR-Positive Breast Cancer. Cancer Treatment Reviews, 115, Article ID: 102529. [Google Scholar] [CrossRef] [PubMed]
[4] Lorenzo, R., Meani, F., Longhitano, C., Carciotto, R., Lanzafame, K., Inzerilli, N., et al. (2023) The Optimal Timing between Neoadjuvant Therapy and Surgery of Breast Cancer: A Brief Systematic Review of the Literature. Critical Reviews in Oncology/Hematology, 183, Article ID: 103921. [Google Scholar] [CrossRef] [PubMed]
[5] Spring, L.M., Bar, Y. and Isakoff, S.J. (2022) The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. Journal of the National Comprehensive Cancer Network, 20, 723-734. [Google Scholar] [CrossRef] [PubMed]
[6] Harbeck, N. (2022) Neoadjuvant and Adjuvant Treatment of Patients with HER2-Positive Early Breast Cancer. The Breast, 62, S12-S16. [Google Scholar] [CrossRef] [PubMed]
[7] Huang, M., O’Shaughnessy, J., Zhao, J., Haiderali, A., Cortés, J., Ramsey, S.D., et al. (2020) Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 80, 5427-5434. [Google Scholar] [CrossRef] [PubMed]
[8] Tarantino, P., Hortobagyi, G., Tolaney, S.M. and Mittendorf, E.A. (2024) Heterogeneity of Residual Disease after Neoadjuvant Systemic Therapy in Breast Cancer: A Review. JAMA Oncology, 10, 1578-1584. [Google Scholar] [CrossRef] [PubMed]
[9] Loi, S., Dafni, U., Karlis, D., Polydoropoulou, V., Young, B.M., Willis, S., et al. (2016) Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. JAMA Oncology, 2, 1040-1047. [Google Scholar] [CrossRef] [PubMed]
[10] Kwon, Y., Nam, K. and Kim, S. (2021) Tamoxifen Overcomes the Trastuzumab-Resistance of SK-BR-3 Tumorspheres by Targeting Crosstalk between Cytoplasmic Estrogen Receptor Α and the EGFR/HER2 Signaling Pathway. Biochemical Pharmacology, 190, Article ID: 114635. [Google Scholar] [CrossRef] [PubMed]
[11] Viganò, L., Locatelli, A., Ulisse, A., Galbardi, B., Dugo, M., Tosi, D., et al. (2022) Modulation of the Estrogen/erbB2 Receptors Cross-Talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor-and Erbb2-Positive Breast Cancer. Clinical Cancer Research, 28, 2167-2179. [Google Scholar] [CrossRef] [PubMed]
[12] Yan, S., Ji, J., Zhang, Z., Imam, M., Chen, H., Zhang, D., et al. (2024) Targeting the Crosstalk between Estrogen Receptors and Membrane Growth Factor Receptors in Breast Cancer Treatment: Advances and Opportunities. Biomedicine & Pharmacotherapy, 175, Article ID: 116615. [Google Scholar] [CrossRef] [PubMed]
[13] Pegram, M., Jackisch, C. and Johnston, S.R.D. (2023) Estrogen/HER2 Receptor Crosstalk in Breast Cancer: Combination Therapies to Improve Outcomes for Patients with Hormone Receptor-Positive/HER2-Positive Breast Cancer. NPJ Breast Cancer, 9, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[14] Vuger, A.T., Tiscoski, K., Apolinario, T. and Cardoso, F. (2022) Anthracyclines in the Treatment of Early Breast Cancer Friend or Foe? The Breast, 65, 67-76. [Google Scholar] [CrossRef] [PubMed]
[15] Early Breast Cancer Trialists’ Collaborative Group (Ebctcg) (2023) Anthracycline-Containing and Taxane-Containing Chemotherapy for Early-Stage Operable Breast Cancer: A Patient-Level Meta-Analysis of 100000 Women from 86 Randomised Trials. The Lancet, 401, 1277-1292.
[16] Gao, Y., Zhang, M., Sun, G., Ma, L., Nie, J., Yuan, Z., et al. (2024) The Features of Male Breast Cancer in China: A Real-World Study. The Breast, 76, Article ID: 103762. [Google Scholar] [CrossRef] [PubMed]
[17] Hurvitz, S.A., McAndrew, N.P., Bardia, A., Press, M.F., Pegram, M., Crown, J.P., et al. (2021) A Careful Reassessment of Anthracycline Use in Curable Breast Cancer. NPJ Breast Cancer, 7, Article No. 134. [Google Scholar] [CrossRef] [PubMed]
[18] Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F. and Colotti, G. (2023) Doxorubicin and Other Anthracyclines in Cancers: Activity, Chemoresistance and Its Overcoming. Molecular Aspects of Medicine, 93, Article ID: 101205. [Google Scholar] [CrossRef] [PubMed]
[19] Alalawy, A.I. (2024) Key Genes and Molecular Mechanisms Related to Paclitaxel Resistance. Cancer Cell International, 24, Article No. 244. [Google Scholar] [CrossRef] [PubMed]
[20] O’Shaughnessy, J., McIntyre, K., Wilks, S., Ma, L., Block, M., Andorsky, D., et al. (2021) Efficacy and Safety of Weekly Paclitaxel with or without Oral Alisertib in Patients with Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Network Open, 4, e214103. [Google Scholar] [CrossRef] [PubMed]
[21] Mo, H., Yan, X., Zhao, F., Teng, Y., Sun, X., Lv, Z., et al. (2022) Association of Taxane Type with Patient-Reported Chemotherapy-Induced Peripheral Neuropathy among Patients with Breast Cancer. JAMA Network Open, 5, e2239788. [Google Scholar] [CrossRef] [PubMed]
[22] Gehr, N.L., Timm, S., Bennedsgaard, K., Grosen, K., Jakobsen, E., Jensen, A.B., et al. (2025) Chronic Chemotherapy-Induced Peripheral Neuropathy and Pain Following Paclitaxel versus Docetaxel in Breast Cancer Survivors: A Cross-Sectional Study. The Breast, 80, Article ID: 104424. [Google Scholar] [CrossRef] [PubMed]
[23] Saleh, R.R., Nadler, M.B., Desnoyers, A., Meti, N., Fazelzad, R. and Amir, E. (2021) Platinum-Based Chemotherapy in Early-Stage Triple Negative Breast Cancer: A Meta-Analysis. Cancer Treatment Reviews, 100, Article ID: 102283. [Google Scholar] [CrossRef] [PubMed]
[24] Palma, M. (2025) Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines, 13, Article No. 344. [Google Scholar] [CrossRef] [PubMed]
[25] Cesca, M.G., Vian, L., Cristóvão-Ferreira, S., Pondé, N. and de Azambuja, E. (2020) HER2-Positive Advanced Breast Cancer Treatment in 2020. Cancer Treatment Reviews, 88, Article ID: 102033. [Google Scholar] [CrossRef] [PubMed]
[26] Swain, S.M., Miles, D., Kim, S.B., et al. (2020) Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study. The Lancet. Oncology, 21, 519-530.
[27] Clark, A.S., Yau, C., Wolf, D.M., Petricoin, E.F., van ‘t Veer, L.J., Yee, D., et al. (2021) Neoadjuvant T-DM1/Pertuzumab and Paclitaxel/Trastuzumab/Pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial. Nature Communications, 12, Article No. 6428. [Google Scholar] [CrossRef] [PubMed]
[28] von Arx, C., De Placido, P., Caltavituro, A., Di Rienzo, R., Buonaiuto, R., De Laurentiis, M., et al. (2023) The Evolving Therapeutic Landscape of Trastuzumab-Drug Conjugates: Future Perspectives Beyond HER2-Positive Breast Cancer. Cancer Treatment Reviews, 113, Article ID: 102500. [Google Scholar] [CrossRef] [PubMed]
[29] Schlam, I., Moges, R., Morganti, S., Tolaney, S.M. and Tarantino, P. (2023) Next-Generation Antibody-Drug Conjugates for Breast Cancer: Moving beyond HER2 and TROP2. Critical Reviews in Oncology/Hematology, 190, Article ID: 104090. [Google Scholar] [CrossRef] [PubMed]
[30] Sun, L., Jia, X., Wang, K. and Li, M. (2024) Unveiling the Future of Breast Cancer Therapy: Cutting-Edge Antibody-Drug Conjugate Strategies and Clinical Outcomes. The Breast, 78, Article ID: 103830. [Google Scholar] [CrossRef] [PubMed]
[31] Rugo, H.S., Bianchini, G., Cortes, J., Henning, J. and Untch, M. (2022) Optimizing Treatment Management of Trastuzumab Deruxtecan in Clinical Practice of Breast Cancer. ESMO Open, 7, Article ID: 100553. [Google Scholar] [CrossRef] [PubMed]
[32] Loibl, S., Huang, C., Mano, M.S., Mamounas, E.P., Geyer, C.E., Untch, M., et al. (2022) Adjuvant Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients with HER2-Negative Residual Invasive Disease in KATHERINE. NPJ Breast Cancer, 8, Article No. 106. [Google Scholar] [CrossRef] [PubMed]
[33] Tarantino, P., Curigliano, G. and Tolaney, S.M. (2022) Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discovery, 12, 2026-2030. [Google Scholar] [CrossRef] [PubMed]
[34] Rakha, E.A., Tan, P.H., Van Bockstal, M.R., Allison, K.H., Brogi, E., Callagy, G., et al. (2026) International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories. Modern Pathology, 39, Article ID: 100925. [Google Scholar] [CrossRef] 
[35] Denkert, C., Seither, F., Schneeweiss, A., Link, T., Blohmer, J., Just, M., et al. (2021) Clinical and Molecular Characteristics of HER2-Low-Positive Breast Cancer: Pooled Analysis of Individual Patient Data from Four Prospective, Neoadjuvant Clinical Trials. The Lancet Oncology, 22, 1151-1161. [Google Scholar] [CrossRef] [PubMed]
[36] Wang, R., Xu, K., Gao, F., Huang, J. and Guan, X. (2021) Clinical Considerations of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188590. [Google Scholar] [CrossRef] [PubMed]
[37] Niu, N., Qiu, F., Xu, Q., He, G., Gu, X., Guo, W., et al. (2022) A Multicentre Single Arm Phase 2 Trial of Neoadjuvant Pyrotinib and Letrozole plus Dalpiciclib for Triple-Positive Breast Cancer. Nature Communications, 13, Article No. 7043. [Google Scholar] [CrossRef] [PubMed]
[38] Tolaney, S.M., Wardley, A.M., Zambelli, S., Hilton, J.F., Troso-Sandoval, T.A., Ricci, F., et al. (2020) Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with Hormone Receptor-Positive, HER2-Positive Advanced Breast Cancer (monarcHER): A Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 21, 763-775. [Google Scholar] [CrossRef] [PubMed]
[39] Asghar, U.S., Kanani, R., Roylance, R. and Mittnacht, S. (2022) Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precision Oncology, 6, e2100002. [Google Scholar] [CrossRef] [PubMed]
[40] Haslam, A., Ranganathan, S., Prasad, V. and Olivier, T. (2024) CDK4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer? Uncertain Benefits, Guaranteed Harms. European Journal of Cancer, 207, Article ID: 114192. [Google Scholar] [CrossRef] [PubMed]
[41] Huang, Z., Beaufort, C., Helmijr, J., Zantboer, B., Rozema, G., Muritti, C., et al. (2026) Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. Cells, 15, Article No. 260. [Google Scholar] [CrossRef] 
[42] Udden, S.N., Wang, Q., Kumar, S., Malladi, V.S., Wu, S., Wei, S., et al. (2022) Targeting ESR1 Mutation-Induced Transcriptional Addiction in Breast Cancer with BET Inhibition. JCI Insight, 7, e151851. [Google Scholar] [CrossRef] [PubMed]
[43] Hamilton, E.P., Patel, M.R., Borges, V.F., Meisel, J.L., Okera, M., Alemany, C.A., et al. (2025) Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2− Advanced or Metastatic Breast Cancer: Phase 1/2 Study Results. Breast Cancer Research, 27, Article No. 119. [Google Scholar] [CrossRef] [PubMed]
[44] Chen, J., Wan, R., Li, Q., Rao, Z., Wang, Y., Zhang, L., et al. (2021) Utilizing the Hippo Pathway as a Therapeutic Target for Combating Endocrine-Resistant Breast Cancer. Cancer Cell International, 21, Article No. 306. [Google Scholar] [CrossRef] [PubMed]
[45] Cai, Y., Zhao, P., Wu, F., Zhao, H., Shao, H., Marra, A., et al. (2025) Inhibition of NR2F2 Restores Hormone Therapy Response to Endocrine Refractory Breast Cancers. Science Translational Medicine, 17, eadk7786. [Google Scholar] [CrossRef] [PubMed]
[46] Blakely, B., Shin, S. and Jin, K. (2023) Overview of the Therapeutic Strategies for ER Positive Breast Cancer. Biochemical Pharmacology, 212, Article ID: 115552. [Google Scholar] [CrossRef] [PubMed]
[47] Huo, S., Xue, J., Wang, S., Shan, H., Chen, G., Niu, N., et al. (2024) A Pilot Trial of Neoadjuvant Pyrotinib plus Trastuzumab, Dalpiciclib, and Letrozole for Triple-Positive Breast Cancer. MedComm, 5, e505. [Google Scholar] [CrossRef] [PubMed]
[48] Huang, J., Wang, H., Tong, Y., Hong, J., Zhu, Y., Ren, W., et al. (2026) Triple HER2 Blockade with Trastuzumab, Pertuzumab, and Pyrotinib versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study. MedComm, 7, e70611. [Google Scholar] [CrossRef] 
[49] Xiao, Y., Ding, J., Ma, D., Chen, S., Li, X. and Yu, K. (2022) Predicting Pathological Complete Response in Neoadjuvant Dual Blockade with Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer. Frontiers in Immunology, 13, Article ID: 877825. [Google Scholar] [CrossRef] [PubMed]
[50] Marra, A., Kim, S.H., Pareja, F., Basili, T., Solit, D.B., Chandarlapaty, S., et al. (2026) Tracking Response to Neoadjuvant Systemic Therapy through Circulating Tumor DNA Analysis in Breast Cancer. NPJ Breast Cancer, 12, Article No. 57. [Google Scholar] [CrossRef] 
[51] Chen, L., Wu, W., Liang, F., Liu, G., Yu, K., Wu, J., et al. (2025) A Prospective, Phase II, Neoadjuvant Study Based on Chemotherapy Sensitivity in HR+/HER2− Breast Cancer‐FINEST Study. Cancer Communications, 45, 411-421. [Google Scholar] [CrossRef] [PubMed]
[52] Wolf, D.M., Yau, C., Wulfkuhle, J., Brown-Swigart, L., Gallagher, R.I., Lee, P.R.E., et al. (2022) Redefining Breast Cancer Subtypes to Guide Treatment Prioritization and Maximize Response: Predictive Biomarkers across 10 Cancer Therapies. Cancer Cell, 40, 609-623.e6. [Google Scholar] [CrossRef] [PubMed]
[53] Luen, S.J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., et al. (2017) Tumour-Infiltrating Lymphocytes in Advanced HER2-Positive Breast Cancer Treated with Pertuzumab or Placebo in Addition to Trastuzumab and Docetaxel: A Retrospective Analysis of the CLEOPATRA Study. The Lancet Oncology, 18, 52-62. [Google Scholar] [CrossRef] [PubMed]
[54] Chumsri, S., Li, Z., Serie, D.J., Norton, N., Mashadi-Hossein, A., Tenner, K., et al. (2022) Adaptive Immune Signature in HER2-Positive Breast Cancer in NCCTG (Alliance) N9831 and NeoALTTO Trials. NPJ Breast Cancer, 8, Article No. 68. [Google Scholar] [CrossRef] [PubMed]
[55] Wang, Q., Guldner, I.H., Golomb, S.M., Sun, L., Harris, J.A., Lu, X., et al. (2019) Single-Cell Profiling Guided Combinatorial Immunotherapy for Fast-Evolving CDK4/6 Inhibitor-Resistant HER2-Positive Breast Cancer. Nature Communications, 10, Article No. 3817. [Google Scholar] [CrossRef] [PubMed]
[56] Zhang, C., Li, N., Zhang, P., et al. (2024) Advancing Precision and Personalized Breast Cancer Treatment through Multi-Omics Technologies. American Journal of Cancer Research, 14, 5614-5627. [Google Scholar] [CrossRef] [PubMed]
[57] Asleh, K., Riaz, N. and Nielsen, T.O. (2022) Heterogeneity of Triple Negative Breast Cancer: Current Advances in Subtyping and Treatment Implications. Journal of Experimental & Clinical Cancer Research, 41, Article No. 265. [Google Scholar] [CrossRef] [PubMed]
[58] Vasic, V., Dickopf, S., Spranger, N., Rosenberger, R., Fischer, M., Mayer, K., et al. (2024) Generation of Binder-Format-Payload Conjugate-Matrices by Antibody Chain-Exchange. Nature Communications, 15, Article No. 9406. [Google Scholar] [CrossRef] [PubMed]
[59] Zhao, M., Liu, W., Lu, W., Li, Z. and Wu, H. (2026) Next-Generation Drug Conjugates for Breast Cancer: Clinical Prospects and Mechanism-Based Strategies to Overcome Resistance. Drug Discovery Today, 31, Article ID: 104599. [Google Scholar] [CrossRef] 
[60] Han, L., Wang, K., Jiang, Z., Guo, X. and Yu, J. (2025) Recent Development in Bispecific Antibody Immunotherapy for Hematological Malignancies. Critical Reviews in Oncology/Hematology, 212, Article ID: 104752. [Google Scholar] [CrossRef] [PubMed]
[61] Beishenaliev, A., Loke, Y.L., Goh, S.J., Geo, H.N., Mugila, M., Misran, M., et al. (2023) Bispecific Antibodies for Targeted Delivery of Anti-Cancer Therapeutic Agents: A Review. Journal of Controlled Release, 359, 268-286. [Google Scholar] [CrossRef] [PubMed]
[62] Zhang, T., Lin, Y. and Gao, Q. (2023) Bispecific Antibodies Targeting Immunomodulatory Checkpoints for Cancer Therapy. Cancer Biology & Medicine, 20, 181-195. [Google Scholar] [CrossRef] [PubMed]
[63] McCue, A.C., Demarest, S.J., Froning, K.J., Hickey, M.J., Antonysamy, S. and Kuhlman, B. (2024) Engineering a Tumor-Selective Prodrug T-Cell Engager Bispecific Antibody for Safer Immunotherapy. mAbs, 16, Article ID: 2373325. [Google Scholar] [CrossRef] [PubMed]
[64] Wang, Z., Zheng, M., Li, M., Lu, H., Liu, N., Chen, Y., et al. (2025) Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors. Molecular Cancer Therapeutics, 24, 261-274. [Google Scholar] [CrossRef] [PubMed]
[65] Wei, J., Yang, Y., Wang, G. and Liu, M. (2022) Current Landscape and Future Directions of Bispecific Antibodies in Cancer Immunotherapy. Frontiers in Immunology, 13, Article ID: 1035276. [Google Scholar] [CrossRef] [PubMed]
[66] Shao, C., Tang, B., Chu, J.C.H., Lau, K.M., Wong, W., Che, C., et al. (2024) Macrophage-Engaging Peptidic Bispecific Antibodies (pBsAbs) for Immunotherapy via a Facile Bioconjugation Strategy. Chemical Science, 15, 11272-11278. [Google Scholar] [CrossRef] [PubMed]
[67] Gu, Y., Wang, Z. and Wang, Y. (2024) Bispecific Antibody Drug Conjugates: Making 1 + 1 > 2. Acta Pharmaceutica Sinica B, 14, 1965-1986. [Google Scholar] [CrossRef] [PubMed]
[68] Khristenko, N.A., Nagornov, K.O., Garcia, C., Gasilova, N., Gant, M., Druart, K., et al. (2025) Top-Down and Middle-Down Mass Spectrometry of Antibodies. Molecular & Cellular Proteomics, 24, Article ID: 100989. [Google Scholar] [CrossRef] [PubMed]
[69] Shimozaki, K., Fukuoka, S., Ooki, A. and Yamaguchi, K. (2024) HER2-Low Gastric Cancer: Is the Subgroup Targetable? ESMO Open, 9, Article ID: 103679. [Google Scholar] [CrossRef] [PubMed]
[70] Ballinger, T.J., Smith, M.L., Railey, E., Zimet, G. and Schneider, B.P. (2024) Discerning the Impact of ctDNA Detection on Patient Decision-Making in Early-Stage Breast Cancer. NPJ Breast Cancer, 10, Article No. 89. [Google Scholar] [CrossRef] [PubMed]

为你推荐